606 related articles for article (PubMed ID: 33528655)
1. [Current state of vaccination against SARS-CoV-2].
Iking-Konert C; Specker C; Krüger K; Schulze-Koops H; Aries P
Z Rheumatol; 2021 Mar; 80(2):158-164. PubMed ID: 33528655
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
3. Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines-A Case Series.
Girbardt C; Busch C; Al-Sheikh M; Gunzinger JM; Invernizzi A; Xhepa A; Unterlauft JD; Rehak M
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835280
[TBL] [Abstract][Full Text] [Related]
4. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
[TBL] [Abstract][Full Text] [Related]
5. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines.
Sølund C; Underwood AP; Fernandez-Antunez C; Bollerup S; Mikkelsen LS; Villadsen SL; Fahnøe U; Winckelmann AA; Feng S; Nørløv Vinten CA; Dalegaard MI; Vizgirda G; Sørensen AL; Ramirez S; Bukh J; Weis N
Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062736
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604
[TBL] [Abstract][Full Text] [Related]
8. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
[TBL] [Abstract][Full Text] [Related]
9. Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2.
Sprute R; Schumacher S; Pauls M; Pauls W; Cornely OA
Drugs R D; 2021 Dec; 21(4):371-374. PubMed ID: 34351606
[TBL] [Abstract][Full Text] [Related]
10. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
[No Abstract] [Full Text] [Related]
11. COVID-19 Vaccine Hesitancy and Early Adverse Events Reported in a Cohort of 7,881 Italian Physicians.
Monami M; Gori D; Guaraldi F; Montalti M; Nreu B; Burioni R; Mannucci E
Ann Ig; 2022; 34(4):344-357. PubMed ID: 34821928
[TBL] [Abstract][Full Text] [Related]
12. Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
Gomes D; Beyerlein A; Katz K; Hoelscher G; Nennstiel U; Liebl B; Überla K; von Kries R
PLoS One; 2021; 16(11):e0259370. PubMed ID: 34739520
[TBL] [Abstract][Full Text] [Related]
13. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
Chagla Z
Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
[TBL] [Abstract][Full Text] [Related]
14. Cancer patients and internal medicine patients attitude towards COVID-19 vaccination in Poland.
Kufel-Grabowska J; Bartoszkiewicz M; Ramlau R; Litwiniuk M
Adv Clin Exp Med; 2021 Aug; 30(8):805-811. PubMed ID: 34286517
[TBL] [Abstract][Full Text] [Related]
15. A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID-19 during a SARS-coronavirus-2 outbreak in a senior citizen home in Germany.
Schwarzer R; Freys SD; Neuwinger N; Beikert N; Eberspächer B; Edelmann A; Zuchowski M; Slothouwer I; Stein A; Theil K; Menzel P; Hofmann J
Immun Inflamm Dis; 2021 Dec; 9(4):1809-1814. PubMed ID: 34528766
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 vaccines in patients with SLE.
Tang W; Askanase AD; Khalili L; Merrill JT
Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33685998
[TBL] [Abstract][Full Text] [Related]
17. [Vaccines against COVID-19].
Fathi A; Mellinghoff SC
Internist (Berl); 2021 Nov; 62(11):1191-1201. PubMed ID: 34613428
[TBL] [Abstract][Full Text] [Related]
18. Covid-19 vaccine management (Comirnaty and mrna-1273 Moderna) in a teaching hospital in Italy: a short report on the vaccination campaign.
Papini F; Grassi N; Guglielmi G; Gattini V; Rago L; Bisordi C; Scateni M; Totaro M; Tulipani A; Porretta A; Tavoschi L; Guercini J; Luchini G; Briani S; Privitera GP; Baggiani A
Environ Health Prev Med; 2021 Sep; 26(1):99. PubMed ID: 34592930
[TBL] [Abstract][Full Text] [Related]
19. [Not Available].
Klimek L; Chaker AM; Cuevas M
Laryngorhinootologie; 2021 Mar; 100(3):168-173. PubMed ID: 33482671
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Infection in Health Care Workers of Trieste (North-Eastern Italy), 1 October 2020-7 February 2022: Occupational Risk and the Impact of the Omicron Variant.
Cegolon L; Ronchese F; Ricci F; Negro C; Larese-Filon F
Viruses; 2022 Jul; 14(8):. PubMed ID: 36016284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
